{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T13:04:59Z","timestamp":1777467899813,"version":"3.51.4"},"reference-count":27,"publisher":"SAGE Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BD"],"published-print":{"date-parts":[[2021,9,30]]},"abstract":"<jats:p>BACKGROUND: Despite the increase in chances of cure for early breast cancer (EBC) patients, approximately 20\u201345% of them will experience a disease recurrence, particularly bone metastases in 60\u201380% of cases, which occur more frequently in luminal subtypes. Endocrine therapy (ET) has always been the milestone of adjuvant treatment for hormone receptor-positive EBC patients, leading to indubitable reduction of disease recurrence risk. However, adjuvant aromatase inhibitors (AIs) therapy may promote a progressive decrease in bone mineral density (BMD), which can lead to osteoporosis. The increased bone resorption associated with osteoporosis may provide fertile soil for cancer growth and accelerate the development of bone metastases. PATIENTS AND METHODS: In this single-institution cohort study, we performed a retrospective analysis of \u201cluminal-like\u201d EBC patients who experienced bone recurrence after a subsequent disease free interval. The aim of the study was to evaluate the median time to skeletal recurrence (TSkR). RESULTS: 143 patients experienced bone recurrence. Median TSkR was 54 months (95%CI: 45\u201365). Among patients who received adjuvant AIs median TSkR was 35 months (95%CI: 25\u201354), while among patients who did not was 61 months (95%CI: 50\u201380) (HR = 1.45 [95%CI: 0.97\u20132.17], p =\u00a00.0644). After adjusting for TNM stage (AJCC 8th edition), adjuvant AIs treatment was significantly related to a shorter TSkR (HR = 1.60 [95%CI: 1.06\u20132.42], p =\u00a00.0244). Adjuvant Tamoxifen, adjuvant AIs\/Tamoxifen and no-treatment did not revealed to be associated to TSkR. CONCLUSIONS: In this cohort of EBC patients with bone recurrence, AIs treatment seems to be related to a shorter TSkR. AIs-induced bone resorption might represent the underlying mechanism.<\/jats:p>","DOI":"10.3233\/bd-201036","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T12:01:21Z","timestamp":1622808081000},"page":"257-262","source":"Crossref","is-referenced-by-count":3,"title":["Bone recurrence in early breast cancer patients: The paradox of aromatase inhibitors induced bone resorption"],"prefix":"10.1177","volume":"40","author":[{"given":"Francesco","family":"Pavese","sequence":"first","affiliation":[{"name":", St. Salvatore Hospital, , Italy"},{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L\u2019Aquila, , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Parisi","sequence":"additional","affiliation":[{"name":", St. Salvatore Hospital, , Italy"},{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L\u2019Aquila, , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Rotondaro","sequence":"additional","affiliation":[{"name":", St. Salvatore Hospital, , Italy"},{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L\u2019Aquila, , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Cocciolone","sequence":"additional","affiliation":[{"name":", St. Salvatore Hospital, , Italy"},{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L\u2019Aquila, , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Pierorazio","sequence":"additional","affiliation":[{"name":", St. Salvatore Hospital, , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Sidoni","sequence":"additional","affiliation":[{"name":", St. Salvatore Hospital, , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucilla","family":"Verna","sequence":"additional","affiliation":[{"name":", St. Salvatore Hospital, , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giampiero","family":"Porzio","sequence":"additional","affiliation":[{"name":", St. Salvatore Hospital, , Italy"},{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L\u2019Aquila, , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corrado","family":"Ficorella","sequence":"additional","affiliation":[{"name":", St. Salvatore Hospital, , Italy"},{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L\u2019Aquila, , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia","family":"Cannita","sequence":"additional","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L\u2019Aquila, , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/BD-201036_ref1","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/91.1.80","article-title":"Dormancy of mammary carcinoma after mastectomy","volume":"91","author":"Karrison","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.3233\/BD-201036_ref2","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.3233\/BD-201036_ref3","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.3349\/ymj.2013.54.5.1168","article-title":"Prognostic factors for patients with bone-only metastasis in breast cancer","volume":"54","author":"Ahn","year":"2013","journal-title":"Yonsei Med J"},{"key":"10.3233\/BD-201036_ref4","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","article-title":"Metastatic behavior of breast cancer subtypes","volume":"28","author":"Kennecke","year":"2010","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.3233\/BD-201036_ref5","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1200\/JCO.2009.26.3756","article-title":"American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer","volume":"28","author":"Burstein","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.3233\/BD-201036_ref6","doi-asserted-by":"publisher","first-page":"7195","DOI":"10.3892\/ol.2018.9561","article-title":"The possible different roles of denosumab in prevention and cure breast cancer bone metastases: a \u2018hypothesis-generator\u2019 study from clinical practice","volume":"16","author":"Cortellini","year":"2018","journal-title":"Oncol Lett"},{"issue":"3","key":"10.3233\/BD-201036_ref7","doi-asserted-by":"publisher","first-page":"R111","DOI":"10.1530\/JOE-19-0077","article-title":"The effects of adjuvant endocrine therapy on bone health in women with breast cancer","volume":"241","author":"Ramchand","year":"2019","journal-title":"J Endocrinol"},{"key":"10.3233\/BD-201036_ref8","first-page":"98","article-title":"The distribution of secondary growths in cancer of the breast","volume":"8","author":"Paget","year":"1889","journal-title":"Cancer Metastasis Rev"},{"key":"10.3233\/BD-201036_ref9","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1002\/cncr.30682","article-title":"Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27","volume":"123","author":"Lipton","year":"2017","journal-title":"Cancer"},{"issue":"6","key":"10.3233\/BD-201036_ref10","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrc3055","article-title":"Cancer to bone: a fatal attraction","volume":"11","author":"Weilbaecher","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"10.3233\/BD-201036_ref11","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1158\/1078-0432.CCR-13-1246","article-title":"Zoledronic acid has differential anti-tumour activity in the pre- and post-menopausal bone microenvironment in vivo","volume":"20","author":"Ottewell","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"3 Suppl","key":"10.3233\/BD-201036_ref12","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1002\/cncr.11132","article-title":"Mechanisms of osteolytic bone metastases in breast carcinoma","volume":"97","author":"K\u00e4k\u00f6nen","year":"2003","journal-title":"Cancer"},{"key":"10.3233\/BD-201036_ref13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1138\/20110487","article-title":"Proteolytic enzymes in metastatic bone disease","volume":"8","author":"Bonfil","year":"2011","journal-title":"IBMS BoneKEy"},{"issue":"11","key":"10.3233\/BD-201036_ref14","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1158\/1078-0432.CCR-14-0576","article-title":"The microenvironment matters: estrogen deficiency fuels cancer bone metastases","volume":"20","author":"Wright","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.3233\/BD-201036_ref15","doi-asserted-by":"publisher","first-page":"8406","DOI":"10.18632\/oncotarget.14139","article-title":"Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo","volume":"8","author":"Wright","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.3233\/BD-201036_ref16","doi-asserted-by":"publisher","first-page":"e190429","DOI":"10.1001\/jamanetworkopen.2019.0429","article-title":"Association of bone metastasis with early-stage breast cancer in women with and without precancer osteoporosis according to osteoporosis therapy status","volume":"2","author":"Chen","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.3233\/BD-201036_ref17","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1245\/s10434-018-6486-6","article-title":"Eighth Edition of the AJCC Cancer Staging Manual: breast cancer","volume":"25","author":"Giuliano","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.3233\/BD-201036_ref18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/pst.1776","article-title":"Effect of correlation on covariate selection in linear and nonlinear mixed effect models","volume":"16","author":"Bonate","year":"2017","journal-title":"Pharmaceut Statist"},{"key":"10.3233\/BD-201036_ref19","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1016\/j.ejca.2006.07.005","article-title":"Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study","volume":"42","author":"Geisler","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.3233\/BD-201036_ref20","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1200\/JCO.2005.05.4882","article-title":"Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCIC CTG MA.17","volume":"24","author":"Perez","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3233\/BD-201036_ref21","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18: a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"key":"10.3233\/BD-201036_ref22","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial","volume":"12","author":"Gnant","year":"2011","journal-title":"Lancet Oncol"},{"issue":"3 Suppl","key":"10.3233\/BD-201036_ref23","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1158\/0008-5472.SABCS11-S1-2","article-title":"Long-term follow-up in ABCSG-12: significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine-receptor-positive early breast cancer","volume":"71","author":"Gnant","year":"2011","journal-title":"Cancer Res"},{"key":"10.3233\/BD-201036_ref24","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Coleman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.3233\/BD-201036_ref25","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ejca.2011.10.021","article-title":"The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials","volume":"48","author":"Yan","year":"2012","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.3233\/BD-201036_ref26","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S1470-2045(18)30862-3","article-title":"Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18: disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Gnant","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.3233\/BD-201036_ref27","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S1470-2045(19)30687-4","article-title":"Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial","volume":"21","author":"Coleman","year":"2019","journal-title":"Lancet Oncol"}],"container-title":["Breast Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/BD-201036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:32:09Z","timestamp":1777383129000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/BD-201036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,30]]},"references-count":27,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3233\/bd-201036","relation":{},"ISSN":["0888-6008","1558-1551"],"issn-type":[{"value":"0888-6008","type":"print"},{"value":"1558-1551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,30]]}}}